Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.
Hideki IwamotoTakashi NiizekiHiroaki NagamatsuKazuomi UeshimaTakako NomuraTeiji KuzuyaKazuhiro KasaiYohei KookaAtsushi HiraokaRie SugimotoTakehiro YonezawaAkio IshiharaAkihiro DeguchiHirotaka AraiShigeo ShimoseTomotake ShironoMasahito NakanoShusuke OkamuraYu NodaNaoki KamachiMiwa SakaiHiroyuki SuzukiHajime AinoNorito MatsukumaSatoru MatsugakiKei OgataYoichi YanoTakato UenoMasahiko KajiwaraSatoshi ItanoKunitaka FukuizumiHiroshi KawanoKazunori NoguchiMasatoshi TanakaTaizo YamaguchiRyoko KuromatsuAtsushi KawaguchiHironori KogaTakuji Torimuranull New Fp Study Groupnull Kurume Liver Cancer Study Group Of JapanPublished in: Cancers (2021)
Local treatment using New-FP is a potentially superior initial treatment compared with sorafenib as a multidisciplinary treatment in locally progressed HCC without EHS.